DIVISION OF OTC DRUG PRODUCTS CENTER FOR DRUG EVALUATION AND RESEARCH

ANNOUNCEMENT OF OTC DRUG FEEDBACK MEETING

1461 '98 JAN 15 P2:27

Representatives of FDA BETWEEN:

and

Representatives of Schering-Plough HealthCare Products

John M. Clayton, Ph.D., Sr. Vice President, Scientific

and Regulatory Affairs

Ronald J. Garutti, M.D., Vice President, Clinical

Research/Regulatory Affairs

Robert Monaghan, Associate Director, Regulatory Affairs

TOPIC:

Ingrown Toenail Relief Final Monograph Amendment*

DATE:

January 20, 1998

TIME:

9:30 a.m.

LOCATION: 9201 Corporate Blvd.

S200

Rockville, MD

Pursuant to the agency's policy statement published in the FEDERAL REGISTER of September 29, 1981 (46 FR 47740) and clarified April 1, 1983 (48 FR 14050) and February 4, 1985 (50 FR 4916), which includes provisions for agency meetings with industry or other interested persons, this feedback meeting is being announced.

All feedback meetings are open to the public and no prior reservation is necessary. For further information or to reconfirm that the meeting has not been rescheduled or canceled, call Mr. Melvin Lessing, 301-827-2271.

ATTENTION: JENNIE BUTLER cc: Docket No. 80N-0295

DATE FORWARDED:

JAN 0 5 1998

*A portion of this meeting will be closed to discuss proprietary information.

80N-0295

CR60